Wilmington, DE – Feb 13, 2025 – Lisen Imprinting Diagnostic, Inc. (LisenID) has entered a know-how agreement with Mayo Clinic to research and develop innovative early cancer diagnostic solutions. This collaboration combines LisenID’s epigenetic imprinting technology with Mayo Clinic’s clinical expertise to address gaps in early cancer detection. LisenID specializes in Quantitative Chromogenic Imprinted Gene In-Situ […]
Read More
Lisen Imprinting’s New Technology Eases Fear for HPV-Positive Patients Breakthrough Published in Cancer Communications (IF=20.1): A Novel Early Cervical Cancer Detection Technology Developed by Lisen Imprinting and Sichuan University West China Second University Hospital Wuxi, China – Lisen Imprinting Diagnostics (Wuxi) Co., Ltd. (“Lisen Imprinting”), in collaboration with Sichuan University West China Second University Hospital, has […]
Read More
On November 20, 2024, the final list of winners for the Delaware EDGE (Encouraging Development, Growth & Expansion) competition was announced, with Lisen Imprint among the honorees. The EDGE Award is granted to only 10 businesses per cycle, recognizing the most outstanding and innovative enterprises in Delaware. The EDGE Award was established by the Delaware […]
Read More